Printer Friendly

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial.

MIDLOTHIAN, Va., March 10 /PRNewswire/ -- PARI's LC STAR nebulizer and PRONEB Ultra II compressor are the exclusive delivery devices for Inspire Pharmaceuticals' second Phase 3 clinical trial for a potential new cystic fibrosis treatment. PARI reusable nebulizers are considered the gold standard for clinical trials and are recommended in commercial sales including AstraZeneca's Pulmicort Respules, Sepracor's Xopenex and Brovana, Novartis' TOBI, Genentech's Pulmozyme, and DEY LP's Accuneb, Duoneb, and Perforomist.

"PARI has a strong track record of reliable and efficient, reproducible drug delivery, so it only makes sense that so many pharmaceutical companies look to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies."

Known as TIGER-2, Inspire's second pivotal Phase 3 clinical trial with denufosol tetrasodium inhalation solution is beginning enrollment in the U.S. and Canada with patients age 5 years and older. The use of standard CF maintenance therapies is permitted during the trial, and additional information is available at http://www.inspirepharm.com/.

The combination of PARI's LC STAR nebulizer and PRONEB Ultra II compressor provides for a quick treatment with high efficiency and minimal medication waste.

It is hoped that denufosol could be the first early intervention therapy available to CF patients that affects an early step in the progression of the disease. Denufosol for the treatment of cystic fibrosis has been granted Fast Track designation and orphan drug status in the United States by the FDA and orphan drug designation in Europe by the European Medicines Agency (EMEA).

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufacturers the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.pari.com/

CONTACT: Ayars & Associates, +1-805-845-5682, or Ashley Weigand, +1-804-253-7274, ext. 711, both for PARI Respiratory Equipment, Inc.

Web site: http://www.pari.com/ http://www.inspirepharm.com/
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 10, 2008
Words:430
Previous Article:MSC.Software Helps Ford Racing Speed Ahead of the Competition With Race Car Vehicle Dynamics Simulation.
Next Article:Sheridan College and Gourmetceuticals Offer Students First Ever Program to Develop Science You Can Eat.
Topics:


Related Articles
PathoGenesis Corp. Begins Clinical Trial Of TOBI in Cystic Fibrosis Patients With Mild Lung Disease.
Aerogen, Inc. Announces Results From Phase 2 Clinical Study Using The Aerodose(R) Albuterol Inhaler.
Corus Pharma Announces Positive Phase II Results for Cystic Fibrosis Drug; Corus 1020 Shows Impact On Pseudomonas Aeruginosa Infections.
PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday.
Inspire's Phase 3 CF Trial, Using PARI's Nebulizer & Compressor, Shows Positive Top-Line Results.
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF.
PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters